ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Recombinant Influenza Vaccine Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-39H15464
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Recombinant Influenza Vaccine Market Research Report 2023
BUY CHAPTERS

Global Recombinant Influenza Vaccine Market Research Report 2024

Code: QYRE-Auto-39H15464
Report
August 2024
Pages:67
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sanofi

Recombinant Influenza Vaccine Market Size

The global Recombinant Influenza Vaccine market was valued at US$ 106.8 million in 2023 and is anticipated to reach US$ 188.4 million by 2030, witnessing a CAGR of 8.5% during the forecast period 2024-2030.

Recombinant Influenza Vaccine Market

Recombinant Influenza Vaccine Market

Recombinant technology plays an important role in the preparation of influenza vaccines. It allows scientists to create and express specific influenza virus proteins through genetic engineering to prepare influenza vaccines. This approach typically involves inserting the genetic sequence of the influenza virus into an expression system, enabling it to produce viral antigen proteins, and then using these proteins to prepare a vaccine.
A significant driver in the Influenza Vaccine market is the growing awareness of the importance of vaccination in preventing seasonal and pandemic influenza outbreaks. As healthcare organizations and governments worldwide promote vaccination as a crucial public health measure, there is an increasing demand for influenza vaccines. Additionally, advances in vaccine research and development, including the production of more effective and broader-spectrum vaccines, are driving market growth. One of the key challenges in this market is the need for frequent vaccine updates to match evolving influenza strains. The virus undergoes genetic changes, requiring annual adjustments to vaccine formulations. This presents logistical challenges for manufacturers in terms of timely production and distribution. Vaccine hesitancy and misinformation also pose challenges by impacting vaccination rates and public perception. Lastly, ensuring equitable access to vaccines, especially in low-income and underserved populations, remains a persistent challenge in the fight against influenza.
This report aims to provide a comprehensive presentation of the global market for Recombinant Influenza Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Influenza Vaccine.

Report Scope

The Recombinant Influenza Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Influenza Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Influenza Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Recombinant Influenza Vaccine Market Report

Report Metric Details
Report Name Recombinant Influenza Vaccine Market
Accounted market size in 2023 US$ 106.8 million
Forecasted market size in 2030 US$ 188.4 million
CAGR 8.5%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Vial
  • Prefilled
Segment by Application
  • Public Sector
  • Private Sector
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Sanofi
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Recombinant Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Recombinant Influenza Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Recombinant Influenza Vaccine Market growing?

Ans: The Recombinant Influenza Vaccine Market witnessing a CAGR of 8.5% during the forecast period 2024-2030.

What is the Recombinant Influenza Vaccine Market size in 2030?

Ans: The Recombinant Influenza Vaccine Market size in 2030 will be US$ 188.4 million.

Who are the main players in the Recombinant Influenza Vaccine Market report?

Ans: The main players in the Recombinant Influenza Vaccine Market are Sanofi

What are the Application segmentation covered in the Recombinant Influenza Vaccine Market report?

Ans: The Applications covered in the Recombinant Influenza Vaccine Market report are Public Sector, Private Sector

What are the Type segmentation covered in the Recombinant Influenza Vaccine Market report?

Ans: The Types covered in the Recombinant Influenza Vaccine Market report are Vial, Prefilled

1 Recombinant Influenza Vaccine Market Overview
1.1 Product Overview and Scope of Recombinant Influenza Vaccine
1.2 Recombinant Influenza Vaccine Segment by Type
1.2.1 Global Recombinant Influenza Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Vial
1.2.3 Prefilled
1.3 Recombinant Influenza Vaccine Segment by Application
1.3.1 Global Recombinant Influenza Vaccine Market Value by Application: (2024-2030)
1.3.2 Public Sector
1.3.3 Private Sector
1.4 Global Recombinant Influenza Vaccine Market Size Estimates and Forecasts
1.4.1 Global Recombinant Influenza Vaccine Revenue 2019-2030
1.4.2 Global Recombinant Influenza Vaccine Sales 2019-2030
1.4.3 Global Recombinant Influenza Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Influenza Vaccine Market Competition by Manufacturers
2.1 Global Recombinant Influenza Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Influenza Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Influenza Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Influenza Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Influenza Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Influenza Vaccine, Product Type & Application
2.7 Recombinant Influenza Vaccine Market Competitive Situation and Trends
2.7.1 Recombinant Influenza Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Influenza Vaccine Players Market Share by Revenue
2.7.3 Global Recombinant Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Influenza Vaccine Retrospective Market Scenario by Region
3.1 Global Recombinant Influenza Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Influenza Vaccine Global Recombinant Influenza Vaccine Sales by Region: 2019-2030
3.2.1 Global Recombinant Influenza Vaccine Sales by Region: 2019-2024
3.2.2 Global Recombinant Influenza Vaccine Sales by Region: 2025-2030
3.3 Global Recombinant Influenza Vaccine Global Recombinant Influenza Vaccine Revenue by Region: 2019-2030
3.3.1 Global Recombinant Influenza Vaccine Revenue by Region: 2019-2024
3.3.2 Global Recombinant Influenza Vaccine Revenue by Region: 2025-2030
3.4 North America Recombinant Influenza Vaccine Market Facts & Figures by Country
3.4.1 North America Recombinant Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Influenza Vaccine Sales by Country (2019-2030)
3.4.3 North America Recombinant Influenza Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Influenza Vaccine Market Facts & Figures by Country
3.5.1 Europe Recombinant Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Influenza Vaccine Sales by Country (2019-2030)
3.5.3 Europe Recombinant Influenza Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Influenza Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Influenza Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Influenza Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Recombinant Influenza Vaccine Market Facts & Figures by Country
3.7.1 Latin America Recombinant Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Influenza Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Influenza Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Recombinant Influenza Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Influenza Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Influenza Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Influenza Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Influenza Vaccine Sales by Type (2019-2030)
4.1.1 Global Recombinant Influenza Vaccine Sales by Type (2019-2024)
4.1.2 Global Recombinant Influenza Vaccine Sales by Type (2025-2030)
4.1.3 Global Recombinant Influenza Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Influenza Vaccine Revenue by Type (2019-2030)
4.2.1 Global Recombinant Influenza Vaccine Revenue by Type (2019-2024)
4.2.2 Global Recombinant Influenza Vaccine Revenue by Type (2025-2030)
4.2.3 Global Recombinant Influenza Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Influenza Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Influenza Vaccine Sales by Application (2019-2030)
5.1.1 Global Recombinant Influenza Vaccine Sales by Application (2019-2024)
5.1.2 Global Recombinant Influenza Vaccine Sales by Application (2025-2030)
5.1.3 Global Recombinant Influenza Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Influenza Vaccine Revenue by Application (2019-2030)
5.2.1 Global Recombinant Influenza Vaccine Revenue by Application (2019-2024)
5.2.2 Global Recombinant Influenza Vaccine Revenue by Application (2025-2030)
5.2.3 Global Recombinant Influenza Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Influenza Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Corporation Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Recombinant Influenza Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sanofi Recombinant Influenza Vaccine Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Influenza Vaccine Industry Chain Analysis
7.2 Recombinant Influenza Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Influenza Vaccine Production Mode & Process
7.4 Recombinant Influenza Vaccine Sales and Marketing
7.4.1 Recombinant Influenza Vaccine Sales Channels
7.4.2 Recombinant Influenza Vaccine Distributors
7.5 Recombinant Influenza Vaccine Customers
8 Recombinant Influenza Vaccine Market Dynamics
8.1 Recombinant Influenza Vaccine Industry Trends
8.2 Recombinant Influenza Vaccine Market Drivers
8.3 Recombinant Influenza Vaccine Market Challenges
8.4 Recombinant Influenza Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Sanofi
List of Tables
    Table 1. Global Recombinant Influenza Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Recombinant Influenza Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Recombinant Influenza Vaccine Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Recombinant Influenza Vaccine Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Recombinant Influenza Vaccine Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Recombinant Influenza Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Recombinant Influenza Vaccine Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Recombinant Influenza Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Recombinant Influenza Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Recombinant Influenza Vaccine, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Recombinant Influenza Vaccine, Product Type & Application
    Table 12. Global Key Manufacturers of Recombinant Influenza Vaccine, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Recombinant Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Influenza Vaccine as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Recombinant Influenza Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Recombinant Influenza Vaccine Sales by Region (2019-2024) & (K Units)
    Table 18. Global Recombinant Influenza Vaccine Sales Market Share by Region (2019-2024)
    Table 19. Global Recombinant Influenza Vaccine Sales by Region (2025-2030) & (K Units)
    Table 20. Global Recombinant Influenza Vaccine Sales Market Share by Region (2025-2030)
    Table 21. Global Recombinant Influenza Vaccine Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Recombinant Influenza Vaccine Revenue Market Share by Region (2019-2024)
    Table 23. Global Recombinant Influenza Vaccine Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Recombinant Influenza Vaccine Revenue Market Share by Region (2025-2030)
    Table 25. North America Recombinant Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Recombinant Influenza Vaccine Sales by Country (2019-2024) & (K Units)
    Table 27. North America Recombinant Influenza Vaccine Sales by Country (2025-2030) & (K Units)
    Table 28. North America Recombinant Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Recombinant Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Recombinant Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Recombinant Influenza Vaccine Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Recombinant Influenza Vaccine Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Recombinant Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Recombinant Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Recombinant Influenza Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Recombinant Influenza Vaccine Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Recombinant Influenza Vaccine Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Recombinant Influenza Vaccine Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Recombinant Influenza Vaccine Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Recombinant Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Recombinant Influenza Vaccine Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Recombinant Influenza Vaccine Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Recombinant Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Recombinant Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Recombinant Influenza Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Recombinant Influenza Vaccine Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Recombinant Influenza Vaccine Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Recombinant Influenza Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Recombinant Influenza Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Recombinant Influenza Vaccine Sales (K Units) by Type (2019-2024)
    Table 51. Global Recombinant Influenza Vaccine Sales (K Units) by Type (2025-2030)
    Table 52. Global Recombinant Influenza Vaccine Sales Market Share by Type (2019-2024)
    Table 53. Global Recombinant Influenza Vaccine Sales Market Share by Type (2025-2030)
    Table 54. Global Recombinant Influenza Vaccine Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Recombinant Influenza Vaccine Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Recombinant Influenza Vaccine Revenue Market Share by Type (2019-2024)
    Table 57. Global Recombinant Influenza Vaccine Revenue Market Share by Type (2025-2030)
    Table 58. Global Recombinant Influenza Vaccine Price (US$/Unit) by Type (2019-2024)
    Table 59. Global Recombinant Influenza Vaccine Price (US$/Unit) by Type (2025-2030)
    Table 60. Global Recombinant Influenza Vaccine Sales (K Units) by Application (2019-2024)
    Table 61. Global Recombinant Influenza Vaccine Sales (K Units) by Application (2025-2030)
    Table 62. Global Recombinant Influenza Vaccine Sales Market Share by Application (2019-2024)
    Table 63. Global Recombinant Influenza Vaccine Sales Market Share by Application (2025-2030)
    Table 64. Global Recombinant Influenza Vaccine Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Recombinant Influenza Vaccine Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Recombinant Influenza Vaccine Revenue Market Share by Application (2019-2024)
    Table 67. Global Recombinant Influenza Vaccine Revenue Market Share by Application (2025-2030)
    Table 68. Global Recombinant Influenza Vaccine Price (US$/Unit) by Application (2019-2024)
    Table 69. Global Recombinant Influenza Vaccine Price (US$/Unit) by Application (2025-2030)
    Table 70. Sanofi Corporation Information
    Table 71. Sanofi Description and Business Overview
    Table 72. Sanofi Recombinant Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 73. Sanofi Recombinant Influenza Vaccine Product
    Table 74. Sanofi Recent Developments/Updates
    Table 75. Key Raw Materials Lists
    Table 76. Raw Materials Key Suppliers Lists
    Table 77. Recombinant Influenza Vaccine Distributors List
    Table 78. Recombinant Influenza Vaccine Customers List
    Table 79. Recombinant Influenza Vaccine Market Trends
    Table 80. Recombinant Influenza Vaccine Market Drivers
    Table 81. Recombinant Influenza Vaccine Market Challenges
    Table 82. Recombinant Influenza Vaccine Market Restraints
    Table 83. Research Programs/Design for This Report
    Table 84. Key Data Information from Secondary Sources
    Table 85. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Recombinant Influenza Vaccine
    Figure 2. Global Recombinant Influenza Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Recombinant Influenza Vaccine Market Share by Type in 2023 & 2030
    Figure 4. Vial Product Picture
    Figure 5. Prefilled Product Picture
    Figure 6. Global Recombinant Influenza Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 7. Global Recombinant Influenza Vaccine Market Share by Application in 2023 & 2030
    Figure 8. Public Sector
    Figure 9. Private Sector
    Figure 10. Global Recombinant Influenza Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 11. Global Recombinant Influenza Vaccine Market Size (2019-2030) & (US$ Million)
    Figure 12. Global Recombinant Influenza Vaccine Sales (2019-2030) & (K Units)
    Figure 13. Global Recombinant Influenza Vaccine Average Price (US$/Unit) & (2019-2030)
    Figure 14. Recombinant Influenza Vaccine Report Years Considered
    Figure 15. Recombinant Influenza Vaccine Sales Share by Manufacturers in 2023
    Figure 16. Global Recombinant Influenza Vaccine Revenue Share by Manufacturers in 2023
    Figure 17. The Global 5 and 10 Largest Recombinant Influenza Vaccine Players: Market Share by Revenue in 2023
    Figure 18. Recombinant Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 19. Global Recombinant Influenza Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 20. North America Recombinant Influenza Vaccine Sales Market Share by Country (2019-2030)
    Figure 21. North America Recombinant Influenza Vaccine Revenue Market Share by Country (2019-2030)
    Figure 22. United States Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 23. Canada Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 24. Europe Recombinant Influenza Vaccine Sales Market Share by Country (2019-2030)
    Figure 25. Europe Recombinant Influenza Vaccine Revenue Market Share by Country (2019-2030)
    Figure 26. Germany Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 27. France Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 28. U.K. Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 29. Italy Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. Russia Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. Asia Pacific Recombinant Influenza Vaccine Sales Market Share by Region (2019-2030)
    Figure 32. Asia Pacific Recombinant Influenza Vaccine Revenue Market Share by Region (2019-2030)
    Figure 33. China Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 34. Japan Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 35. South Korea Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 36. India Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. Australia Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. China Taiwan Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. Southeast Asia Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Latin America Recombinant Influenza Vaccine Sales Market Share by Country (2019-2030)
    Figure 41. Latin America Recombinant Influenza Vaccine Revenue Market Share by Country (2019-2030)
    Figure 42. Mexico Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Brazil Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Argentina Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Colombia Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Middle East & Africa Recombinant Influenza Vaccine Sales Market Share by Country (2019-2030)
    Figure 47. Middle East & Africa Recombinant Influenza Vaccine Revenue Market Share by Country (2019-2030)
    Figure 48. Turkey Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Saudi Arabia Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. UAE Recombinant Influenza Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 51. Global Sales Market Share of Recombinant Influenza Vaccine by Type (2019-2030)
    Figure 52. Global Revenue Market Share of Recombinant Influenza Vaccine by Type (2019-2030)
    Figure 53. Global Recombinant Influenza Vaccine Price (US$/Unit) by Type (2019-2030)
    Figure 54. Global Sales Market Share of Recombinant Influenza Vaccine by Application (2019-2030)
    Figure 55. Global Revenue Market Share of Recombinant Influenza Vaccine by Application (2019-2030)
    Figure 56. Global Recombinant Influenza Vaccine Price (US$/Unit) by Application (2019-2030)
    Figure 57. Recombinant Influenza Vaccine Value Chain
    Figure 58. Recombinant Influenza Vaccine Production Process
    Figure 59. Channels of Distribution (Direct Vs Distribution)
    Figure 60. Distributors Profiles
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions